PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapies. It advances the next generation of oligonucleotide therapeutics designed to transform the treatment of severe neuromuscular and neurologic diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The company focuses on proprietary platforms that enable enhanced delivery and efficacy of these therapies through clinical trials such as the FREEDOM and CONNECT studies. PepGen Inc. targets unmet needs in rare genetic disorders by innovating splicing correction and exon skipping mechanisms to address underlying disease causes. Its pipeline emphasizes precision medicine approaches for patients with limited treatment options. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen Inc. operates within the health technology sector, contributing to advancements in biotechnology for neuromuscular conditions.